Jiahui International Hospital has announced that the world's first international patient receiving solid-tumor CAR-T therapy has completed standardized treatment at its center. The patient traveled from Russia after multiple prior treatment lines; following multidisciplinary indication assessment at the Jiahui International Cell Therapy Center, he entered the treatment pathway.
The full journey covered: international medical record review and molecular-pathology confirmation → leukapheresis and cell manufacturing cycle coordination → bridging therapy and infusion management → standardized post-discharge follow-up. Jiahui provided Russian-language medical coordination and maintained remote communication with the patient's home-country physician for continuity of care.
The significance: international delivery of solid-tumor CAR-T no longer depends on clinical trial access — patients receive standardized clinical care based on an approved drug. For overseas patients considering treatment in China, Shanghai is becoming one of the most accessible destinations for cell therapy. MedBridge Shanghai assists with medical record pre-screening, hospital liaison, twelve-language accompaniment and full follow-up coordination.
How MedBridge Shanghai Helps
As a leading cross-border medical platform in Shanghai, MedBridge Shanghai provides end-to-end support: free medical record review and specialist appointments, pre-travel coordination and visa support, airport pickup and accommodation, full medical interpretation and coordination, and post-treatment follow-up with remote consultations.
For more information on CAR-T treatment options and costs, contact our medical advisors, or explore our medical services and partner hospitals.
[Disclaimer] This article is not medical advice. Indications, costs and availability of cell therapy must be confirmed by in-person physician evaluation and the hospital's official plan.